Bimatoprost
Title: Bimatoprost
CAS Registry Number: 155206-00-1
CAS Name: (5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide
Additional Names: (5Z,9a,11a,13E,15S)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprosta-5,13-dienoic acid ethylamide; 17-phenyl-18,19,20-trinorprostaglandin F2a ethylamide
Manufacturers' Codes: AGN-192024
Trademarks: Lumigan (Allergan)
Molecular Formula: C25H37NO4
Molecular Weight: 415.57
Percent Composition: C 72.25%, H 8.97%, N 3.37%, O 15.40%
Literature References: Synthetic prostamide; structurally related to prostaglandin F2a, q.v. Prepn: D. F. Woodward et al., WO 9406433; eidem, US 6403649 (1994, 2002 both to Allergan). Series of articles on pharmacology and clinical experience: Surv. Ophthalmol. 45, Suppl. 4, S335-S368 (2001). Pharmacology: D. F. Woodward et al., J. Pharmacol. Exp. Ther. 305, 772 (2003). Clinical comparison with timolol in glaucoma and ocular hypertension: J. D. Brandt et al., Ophthalmology 108, 1023 (2001). Clinical trial in glaucoma and ocular hypertension: R. Quinones et al., J. Ocul. Pharmacol. Ther. 20, 115 (2004). Review of pharmacology and clinical efficacy: L. B. Cantor, Expert Opin. Invest. Drugs 10, 721-731 (2001); of mechanism of action: A. H.-P. Krauss, D. F. Woodward, Surv. Ophthalmol. 49, Suppl. 1, S5-S11 (2004): of pharmacoeconomics of use: G. L. Plosker, S. J. Keam, Pharmacoeconomics 24, 297-314 (2006).
Properties: Powder. Very sol in ethanol, methanol; slightly sol in water.
Therap-Cat: Antiglaucoma.
Keywords: Antiglaucoma; Prostaglandin/Prostaglandin Analog.

Others monographs:
2,4-DinitroanilineSuclofenideBietanautineTrehalose
Quinupraminen-Butyl Iodide4-Amino-3-hydroxybutyric AcidCactus Grandiflorus
Gold StannateCarbacholAjmalineCyclosporins
PolifeprosanCoumarin-3-carboxylic AcidPropylenediamineGuanidine
©2016 DrugLead US FDA&EMEA